Mood stabilizer psychopharmacology

Clinical Neuroscience Research

Volumn 2, Issue 3-4, 2002, Pages 193-212

  Gould, Todd D ^a   Chen, Guang ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Anticonvulsant; Antiepileptic; bcl 2; Bipolar disorder; Depression; ERK; Mania; Mood stabilizer; Neuroprotection; Neurotrophic; Protein kinase C; Valproate

Indexed keywords

ANTIDEPRESSANT AGENT; ARACHIDONIC ACID; CARBAMAZEPINE; ENZYME INHIBITOR; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; INOSITOL PHOSPHATE; ION CHANNEL; LITHIUM; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE C; TAMOXIFEN; UNCLASSIFIED DRUG; VALPROIC ACID; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIPOLAR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME METABOLISM; ENZYME REGULATION; HUMAN; MANIA; NERVE CELL PLASTICITY; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOPHARMACOLOGY; RAT; REVIEW; SIDE EFFECT;

EID: 0036893028     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1566-2772(02)00044-0     Document Type: Review

References (248)

1. Keck Jr PE, Manji HK. Current and emerging treatments for acute mania and long-term prophylaxis for bipolar disorder. In: Davis KL, Charney DS, Coyle JT, Nemeroff CB, editors. Neuropsychopharmacology: the fifth generation of progress, Philadelphia, PA: Lippincott Williams and Wilkins, 2002. pp. 1109-1118.
2. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat KA, Chen G. Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications. J Clin Psychiatry 1999;60(Suppl 2):27-39 discussion pp 40-1, 113-6.
3. Gould TD, Manji HK. Signaling networks in the pathophysiology and treatment of mood disorders. J Psychosom Res 2002;53(2):687-697.
4. Bowden CL. Toward an integrated biological model of bipolar disorder. In: Young LT, Joffe RT, editors. Bipolar disorder: biological models and their clinical application, New York: Marcel Dekker, 1997. pp. 235-254.
5. Manji HK, Lenox RH. Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 2000;48(6):518-530.
6. Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001;7(5):541-547.
7. Waldmeier PC. Is there a common denominator for the antimanic effect of lithium and anticonvulsants? Pharmacopsychiatry 1987;20(2):37-47.
8. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J Neurochem 1994;63(6):2361-2364.
9. Lenox RH, McNamara RK, Watterson JM, Watson DG. Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry 1996;57(Suppl 13-10):23-33.
10. Manji HK, Chen G, Hsiao JK, Risby ED, Masana MI, Potter WZ. Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry 1996;57(13):34-48.
11. Post RM. Psychopharmacology of mood stabilizers. In: Buckley BF, Waddington JL, editors. Schizophrenia and mood disorders: the new drug therapies in clinical practice, Oxford: Butterworth-Heinemann, 2000. pp. 127-154.
12. Jope RS. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999;4(2):117-128.
13. Wang J-F, Young LT, Li PP, Warsh JJ. Signal transduction abnormalities in bipolar disorder. In: Young LT, Joffe RT, editors. Bipolar disorder: biological models and their clinical application, New York: Marcel Dekker, 1997. pp. 41-79.
14. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002;417(6886):292-295.
15. Hall AC, Brennan A, Goold RG, Cleverley K, Lucas FR, Gordon-Weeks PR, et al. Valproate regulates GSK-3-mediated axonal remodeling and synapsin i clustering in developing neurons. Mol Cell Neurosci 2002;20(2):257-270.
16. Amari L, Layden B, Rong Q, Geraldes CF, Mota de Freitas D. Comparison of fluorescence, (31)P NMR, and (7)Li NMR spectroscopic methods for investigating Li(1)/Mg(2 1 ) competition for biomolecules. Anal Biochem 1999;272(1):1-7.
17. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001;280(3):720-725.
18. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351(3 Pt 1):95-105.
19. York JD, Ponder JW, Majerus PW. Definition of a metal-dependent/ Li(1)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc Natl Acad Sci USA 1995;92(11):5149-5153.
20. Masuda CA, Xavier MA, Mattos KA, Galina A, Montero-Lomeli M. Phosphoglucomutase is an in vivo lithium target in yeast. J Biol Chem 2001;10:10.
21. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996;93(16):8455-8459.
22. Li X, Ketter TA, Frye MA. Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J Affect Disord 2002;69(1-3) :1-14.
23. Post RM, Denicoff KD, Frye MA, Dunn RT, Leverich GS, Osuch E, et al. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology 1998;38(3):152-166.
24. Spiegel AM. G proteins, receptors, and disease. Totowa, NJ: Humana, 1998.
25. Manji HK. G proteins: implications for psychiatry. Am J Psychiatry 1992;149(6):746-760.
26. Warsh JJ, Young LT, Li PP. Bipolar medications: mechanisms of action. In: Manji HK, Bowden CL, Belmaker RH, editors. 1st ed. Washington, DC: American Psychiatric Press, 2000. pp. 299-329.
27. Casebolt TL, Li XH, Jope RS. Alpha-1 adrenergic receptor binding and adrenergic-stimulated cyclic AMP production in rat cerebral cortex after chronic lithium treatment. J Neural Transm Gen Sect 1990;82(3):197-204.
28. Colin SF, Chang HC, Mollner S, Pfeuffer T, Reed RR, Duman RS, et al. Chronic lithium regulates the expression of adenylate cyclase and Gi- protein alpha subunit in rat cerebral cortex. Proc Natl Acad Sci USA 1991;88(23):10634-10637.
29. Jakobsen SN, Wiborg O. Selective effects of long-term lithium and carbamazepine administration on G-protein subunit expression in rat brain. Brain Res 1998;780(1):46-55.
30. Li PP, Young LT, Tam YK, Sibony D, Warsh JJ. Effects of chronic lithium and carbamazepine treatment on G-protein subunit expression in rat cerebral cortex. Biol Psychiatry 1993;34(3):162-170.
31. Masana MI, Bitran JA, Hsiao JK, Potter WZ. In vivo evidence that lithium inactivates Gi modulation of adenylate cyclase in brain. J Neurochem 1992;59(1):200-205.
32. Ebstein RP, Oppenheim G, Ebstein BS, Amiri Z, Stessman J. The cyclic AMP second messenger system in man: the effects of heredity, hormones, drugs, aluminum, age and disease on signal amplification. Prog Neuropsychopharmacol Biol Psychiatry 1986;10(3-5):323-353.
33. Newman ME, Lerer B, Lichtenberg P, Shapira B. Platelet adenylate cyclase activity in depression and after clomipramine and lithium treatment: relation to serotonergic function. Psychopharmacology 1992;109(1-2):231-234.
34. Risby ED, Hsiao JK, Manji HK, Bitran J, Moses F, Zhou DF, et al. The mechanisms of action of lithium. II. Effects on adenylate cyclase activity and beta-adrenergic receptor binding in normal subjects. Arch Gen Psychiatry 1991;48(6):513-524.
35. Ebstein RP, Moscovich D, Zeevi S, Amiri Z, Lerer B. Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: postreceptor modification of second messenger signal amplification. Psychiatry Res 1987;21(3):221-228.
36. Hsiao JK, Manji HK, Chen GA, Bitran JA, Risby ED, Potter WZ. Lithium administration modulates platelet Gi in humans. Life Sci 1992;50(3):227-233.
37. Lonati-Galligani M, Emrich HM, Raptis C, Pirke KM. Effect of in vivo lithium treatment on (2)isoproterenol-stimulated cAMP accumulation in lymphocytes of healthy subjects and patients with affective psychoses. Pharmacopsychiatry 1989;22(6):241-245.
38. Wang YC, Pandey GN, Mendels J, Frazer A. Effect of lithium on prostaglandin F1-stimulated adenylate cyclase activity of human platelets. Biochem Pharmacol 1974;23(4):845-855.
39. Garcia-Sevilla JA, Guimon J, Garcia-Vallejo P, Fuster MJ. Biochemical and functional evidence of supersensitive platelet alpha 2-adrenoceptors in major affective disorder. Effect of longterm lithium carbonate treatment. Arch Gen Psychiatry 1986;43(1):51-57.
40. Kofman O, Li PP, Warsh JJ. Lithium, but not carbamazepine, potentiates hyperactivity induced by intra-accumbens cholera toxin. Pharmacol Biochem Behav 1998;59(1):191-200.
41. Miki M, Hamamura T, Ujike H, Lee Y, Habara T, Kodama M, et al. Effects of subchronic lithium chloride treatment on G-protein subunits (Golf, Ggamma7) and adenylyl cyclase expressed specifically in the rat striatum. Eur J Pharmacol 2001;428(3):303-309.
42. Herve D, Levi-Strauss M, Marey-Semper I, Verney C, Tassin JP, Glowinski J, et al. G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase. J Neurosci 1993;13(5):2237-2248.
43. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways. Molecular targets for lithium's actions. Arch Gen Psychiatry 1995;52(7):531-543.
44. Mork A, Geisler A, Hollund P. Effects of lithium on second messenger systems in the brain. Pharmacol Toxicol 1992;71(Suppl 1):4-17.
45. Chen G, Masana MI, Manji HK. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord 2000;2(3 Pt 2):217-236.
46. Manji HK, Chen G, Shimon H, Hsiao JK, Potter WZ, Belmaker RH. Guanine nucleotide-binding proteins in bipolar affective disorder. Effects of long-term lithium treatment. Arch Gen Psychiatry 1995;52(2):135-144.
47. Li PP, Andreopoulos S, Warsh JJ. Signal transduction abnormalities in bipolar affective disorder. In: Reith MEA, editor. Cerebral signal transduction: from first to fourth messengers, Totowa, NJ: Humana, 2000. pp. 283-312.
48. Jope RS. A bimodal model of the mechanism of action of lithium. Mol Psychiatry 1999;4(1):21-25.
49. Wiborg O, Kruger T, Jakobsen SN. Region-selective effects of longterm lithium and carbamazepine administration on cyclic AMP levels in rat brain. Pharmacol Toxicol 1999;84(2):88-93.
50. Manji HK, Chen G. Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders. Curr Psychiatry Rep 2000;2(6):479-489.
51. Ram A, Guedj F, Cravchik A, Weinstein L, Cao Q, Badner JA, et al. No abnormality in the gene for the G protein stimulatory alpha subunit in patients with bipolar disorder. Arch Gen Psychiatry 1997;54(1):44-48.
52. Manji HK, Chen G, Hsiao JK, Masana MI, Moore GJ, Potter WZ. Regulation of signal transduction pathways by mood stabilizing agents: implications for the pathophysiology and treatment of bipolar affective disorder. In: Manji HK, Bowden CL, Belmaker RH, editors. Bipolar medications: mechanisms of action, 1st ed. Washington, DC: American Psychiatric Press, 2000. pp. 129-177.
53. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002;27(1-2) :121-130.
54. Palmer GC. Interactions of antiepileptic drugs on adenylate cyclase and phosphodiesterases in rat and mouse cerebrum. Exp Neurol 1979;63(2):322-335.
55. Palmer GC, Jones DJ, Medina MA, Stavinoha WB. Anticonvulsant drug actions on in vitro and in vivo levels of cyclic AMP in the mouse brain. Epilepsia 1979;20(2):95-104.
56. Elphick M, Taghavi Z, Powell T, Godfrey PP. Chronic carbamazepine down-regulates adenosine A2 receptors: studies with the putative selective adenosine antagonists PD115,199 and PD116,948. Psychopharmacology 1990;100(4):522-529.
57. Van Calker D, Steber R, Klotz KN, Greil W. Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses. Eur J Pharmacol 1991;206(4):285-290.
58. Lewin E, Bleck V. Cyclic AMP accumulation in cerebral cortical slices: effect of carbamazepine, phenobarbital, and phenytoin. Epilepsia 1977;18(2):237-242.
59. Ferrendelli JA, Kinscherf DA. Inhibitory effects of anticonvulsant drugs on cyclic nucleotide accumulation in brain. Ann Neurol 1979;5(6):533-538.
60. Avissar S, Schreiber G, Aulakh CS, Wozniak KM, Murphy DL. Carbamazepine and electroconvulsive shock attenuate beta-adrenoceptor and muscarinic cholinoceptor coupling to G proteins in rat cortex. Eur J Pharmacol 1990;189(1):99-103.
61. Chen G, Pan B, Hawver DB, Wright CB, Potter WZ, Manji HK. Attenuation of cyclic AMP production by carbamazepine. J Neurochem 1996;67(5):2079-2086.
62. Divish MM, Sheftel G, Boyle A, Kalasapudi VD, Papolos DF, Lachman HM. Differential effect of lithium on fos protooncogene expression mediated by receptor and postreceptor activators of protein kinase C and cyclic adenosine monophosphate: model for its antimanic action. J Neurosci Res 1991;28(1):40-48.
63. Ludvig N, Mishra PK, Jobe PC. Dibutyryl cyclic AMP has epileptogenic potential in the hippocampus of freely behaving rats: a combined EEG-intracerebral microdialysis study. Neurosci Lett 1992;141(2):187-191.
64. Chen G, Manji HK, Wright CB, Hawver DB, Potter WZ. Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology 1996;15(3):271-280.
65. Hudson CJ, Young LT, Li PP, Warsh JJ. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 1993;13(3):278-293.
66. Hallcher LM, Sherman WR. The effects of lithium ion and other agents on the activity of myo- inositol-1-phosphatase from bovine brain. J Biol Chem 1980;255(22):10896-10901.
67. Naccarato WF, Ray RE, Wells WW. Biosynthesis of myo-inositol in rat mammary gland. Isolation and properties of the enzymes. Arch Biochem Biophys 1974;164(1):194-201.
68. Majerus PW. Inositol phosphate biochemistry. Annu Rev Biochem 1992;61:225-250.
69. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989;59(3):411-419.
70. Gani D, Downes CP, Batty I, Bramham J. Lithium and myo-inositol homeostasis. Biochim Biophys Acta 1993;1177(3):253-269.
71. Allison JH, Stewart MA. Reduced brain inositol in lithium-treated rats. Nat New Biol 1971;233(43):267-268.
72. Atack JR. Lithium, phosphatidylinositol signaling, and bipolar disorder. In: Manji HK, Bowden CL, Belmaker RH, editors. Bipolar medications: mechanism of action, 1st ed. Washington, DC: American Psychiatric Press, 2000.
73. Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, Arfken CL, Strahl-Bevacqua J, et al. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manicdepressive illness. Am J Psychiatry 1999;156(12):1902-1908.
74. Chen G, Hasanat KA, Bebchuk JM, Moore GJ, Glitz D, Manji HK. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med 1999;61(5):599-617.
75. Fauroux CM, Freeman S. Inhibitors of inositol monophosphatase. J Enzyme Inhib 1999;14(2):97-108.
76. Godfrey PP, McClue SJ, White AM, Wood AJ, Grahame-Smith DG. Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex. J Neurochem 1989;52(2):498-506.
77. Song L, Jope RS. Chronic lithium treatment impairs phosphatidylinositol hydrolysis in membranes from rat brain regions. J Neurochem 1992;58(6):2200-2206.
78. Manji HK, Lenox RH. Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 1994;16(1):11-28.
79. Jope RS, Williams MB. Lithium and brain signal transduction systems. Biochem Pharmacol 1994;47(3):429-441.
80. Vaden DL, Ding D, Peterson B, Greenberg ML. Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J Biol Chem 2001;276(18):15466-15471.
81. Murray M, Greenberg ML. Expression of yeast INM1 encoding inositol monophosphatase is regulated by inositol, carbon source and growth stage and is decreased by lithium and valproate. Mol Microbiol 2000;36(3):651-661.
82. van Calker D, Belmaker RH. The high affinity inositol transport system - implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disord 2000;2(2):102-107.
83. Lubrich B, van Calker D. Inhibition of the high affinity myo-inositol transport system: a common mechanism of action of antibipolar drugs? Neuropsychopharmacology 1999;21(4):519-529.
84. Coyle JT, Manji HK. Getting balance: drugs for bipolar disorder share target. Nat Med 2002;8(6):557-558.
85. Manji HK, Lenox RH. Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol Psychiatry 1999;46(10):1328-1351.
86. Manji HK, Bersudsky Y, Chen G, Belmaker RH, Potter WZ. Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositol. Neuropsychopharmacology 1996;15(4):370-381.
87. Manji HK, Etcheberrigaray R, Chen G, Olds JL. Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J Neurochem 1993;61(6):2303-2310.
88. Leli U, Hauser G. Lithium modifies diacylglycerol levels and protein kinase C in neuroblastoma cells. Abstracts of the 8th international conference on second messengers and phosphoproteins, 1992. p. Z187F.
89. Li X, Jope RS. Selective inhibition of the expression of signal transduction proteins by lithium in nerve growth factor-differentiated PC12 cells. J Neurochem 1995;65(6):2500-2508.
90. Lenox RH, Watson DG, Patel J, Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992;570(1-2):333-340.
91. Watson DG, Lenox RH. Chronic lithium-induced down-regulation of MARCKS in immortalized hippocampal cells: potentiation by muscarinic receptor activation. J Neurochem 1996;67(2):767-777.
92. Watson DG, Watterson JM, Lenox RH. Sodium valproate downregulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers. J Pharmacol Exp Ther 1998;285(1):307-316.
93. Einat H, Kofman O, Belmaker RH. Animal models of bipolar disorder: from a single episode to progressive cycling models. In: Myslobodsky M, Weiner I, editors. Contemporary issues in modeling psychopathology, London: Kluwer Academic Publishers, 2000. pp. 165-179.
94. Post RM, Susan R, Weiss B. Sensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness. Pharmacopsychiatry 1992;25(1):41-43.
95. Lenox RH, Gould TD, Manji HK. Endophenotype in bipolar disorder. Am J Med Genet 2002;114(4):391-406.
96. Steketee JD, Striplin CD, Murray TF, Kalivas PW. Possible role for G-proteins in behavioral sensitization to cocaine. Brain Res 1991;545(1-2):287-291.
97. Steketee JD, Kalivas PW. Sensitization to psychostimulants and stress after injection of pertussis toxin into the A10 dopamine region. J Pharmacol Exp Ther 1991;259(2):916-924.
98. Steketee JD. Injection of the protein kinase inhibitor H7 into the A10 dopamine region blocks the acute responses to cocaine: behavioral and in vivo microdialysis studies. Neuropharmacology 1993;32(12):1289-1297.
99. Steketee JD. Intra-A10 injection of H7 blocks the development of sensitization to cocaine. Neuroreport 1994;6(1):69-72.
100. Giambalvo CT. Protein kinase C and dopamine transport - 2. Effects of amphetamine in vitro. Neuropharmacology 1992;31(12):1211-1222.
101. Giambalvo CT. Protein kinase C and dopamine transport - 1. Effects of amphetamine in vivo. Neuropharmacology 1992;31(12):1201-1210.
102. Gnegy ME, Hong P, Ferrell ST. Phosphorylation of neuromodulin in rat striatum after acute and repeated, intermittent amphetamine. Brain Res Mol Brain Res 1993;20(4):289-298.
103. Iwata SI, Hewlett GH, Ferrell ST, Kantor L, Gnegy ME. Enhanced dopamine release and phosphorylation of synapsin I and neuromodulin in striatal synaptosomes after repeated amphetamine. J Pharmacol Exp Ther 1997;283(3):1445-1452.
104. Iwata S, Hewlett GH, Gnegy ME. Amphetamine increases the phosphorylation of neuromodulin and synapsin I in rat striatal synaptosomes. Synapse 1997;26(3):281-291.
105. Daigen A, Akiyama K, Itoh T, Kohira I, Sora I, Morimoto K, et al. Long-lasting enhancement of the membrane-associated protein kinase C activity in the hippocampal kindled rat. Jpn J Psychiatry Neurol 1991;45(2):297-301.
106. Daigen A, Akiyama K, Otsuki S. Long-lasting change in the membrane-associated protein kinase C activity in the hippocampal kindled rat. Brain Res 1991;545(1-2):131-136.
107. Kantor L, Gnegy ME. Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther 1998;284(2):592-598.
108. Plotsky PM, Owens MJ, Nemeroff CB. Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am 1998;21(2):293-307.
109. Ur E, Turner TH, Goodwin TJ, Grossman A, Besser GM. Mania in association with hydrocortisone replacement for Addison's disease. Postgrad Med J 1992;68(795):41-43.
110. Haskett RF. Diagnostic categorization of psychiatric disturbance in Cushing's syndrome. Am J Psychiatry 1985;142(8):911-916.
111. Dwivedi Y, Pandey GN. Administration of dexamethasone up-regulates protein kinase C activity and the expression of gamma and epsilon protein kinase C isozymes in the rat brain. J Neurochem 1999;72(1):380-387.
112. Nalepa I, Vetulani J. The responsiveness of cerebral cortical adrenergic receptors after chronic administration of atypical antidepressant mianserin. J Psychiatry Neurosci 1994;19(2):120-128.
113. Nalepa I, Chalecka-Franaszek E, Vetulani J. The antagonistic effect of separate and consecutive chronic treatment with imipramine and ECS on the inhibition of alpha 1-adrenoceptor activity by protein kinase C. Pol J Pharmacol 1993;45(5-6):521-532.
114. Apparsundaram S, Schroeter S, Giovanetti E, Blakely RD. Acute regulation of norepinephrine transport: II. PKC-modulated surface expression of human norepinephrine transporter proteins. J Pharmacol Exp Ther 1998;287(2):744-751.
115. Apparsundaram S, Galli A, De Felice LJ, Hartzell HC, Blakely RD. Acute regulation of norepinephrine transport: I. protein kinase C-linked muscarinic receptors influence transport capacity and transporter density in SK-N-SH cells. J Pharmacol Exp Ther 1998;287(2):733-743.
116. Blakely RD, Ramamoorthy S, Schroeter S, Qian Y, Apparsundaram S, Galli A, et al. Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol Psychiatry 1998;44(3):169-178.
117. Zhang L, Elmer LW, Little KY. Expression and regulation of the human dopamine transporter in a neuronal cell line. Brain Res Mol Brain Res 1998;59(1):66-73.
118. Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990.
119. Chen SJ, Sweatt JD, Klann E. Enhanced phosphorylation of the postsynaptic protein kinase C substrate RC3/neurogranin during long-term potentiation. Brain Res 1997;749(2):181-187.
120. Conn PJ, Sweatt JD. Protein kinase C in the nervous system. In: Kuo JF, editor. Protein kinase C, New York: Oxford University Press, 1994. pp. 199-235.
121. Hahn CG, Friedman E. Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord 1999;1(2):81-86.
122. Bebchuk JM, Arfken CL, Dolan-Manji S, Murphy J, Hasanat K, Manji HK. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch Gen Psychiatry 2000;57(1):95-97.
123. Horgan K, Cooke E, Hallett MB, Mansel RE. Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity. Biochem Pharmacol 1986;35(24):4463-4465.
124. O'Brian CA, Housey GM, Weinstein IB. Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. Cancer Res 1988;48(13):3626-3629.
125. Cohen P, Frame S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001;2(10):769-776.
126. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR. Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta 1992;1114(2-3):147-162.
127. Woodgett JR. Judging a protein by more than its name: gsk-3. Sci STKE 2001;1(200(100)):RE12.
128. Haugaard ES, Mickel RA, Haugaard N. Actions of lithium ions and insulin on glucose utilization, glycogen synthesis and glycogen synthase in the isolated rat diaphragm. Biochem Pharmacol 1974;23(12):1675-1685.
129. Cheng K, Creacy S, Larner J. 'Insulin-like' effects of lithium ion on isolated rat adipocytes. II. Specific activation of glycogen synthase. Mol Cell Biochem 1983;56(2):183-189.
130. Bosch F, Gomez-Foix AM, Arino J, Guinovart JJ. Effects of lithium ions on glycogen synthase and phosphorylase in rat hepatocytes. J Biol Chem 1986;261(36):16927-16931.
131. Harwood AJ. Regulation of GSK-3: a cellular multiprocessor. Cell 2001;105(7):821-824.
132. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001;65(4):391-426.
133. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11(24):3286-3305.
134. Salinas PC, Hall AC. Lithium and synaptic plasticity. Bipolar Disord 1999;1(2):87-90.
135. Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist 2002;8(5):497-511.
136. Li X, Bijur GN, Jope RS. Glycogen synthase kinase 3-beta, mood stabilizers, and neuroprotection. Bipolar Disord 2002;4:137-144.
137. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000;5(6):578-593.
138. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001;41:789-813.
139. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999;72(3):1327-1330.
140. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;25:25.
141. Grimes AC, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3beta and facilitated by lithium. J Neurochem 2001;78:1-15.
142. Axelrod J, Burch RM, Jelsema CL. Receptor-mediated activation of phospholipase A2 via GTP-binding proteins: arachidonic acid and its metabolites as second messengers. Trends Neurosci 1988;11(3):117-123.
143. Rapoport SI. In vivo fatty acid incorporation into brain phospholipids in relation to plasma availability, signal transduction and membrane remodeling. J Mol Neurosci 2001;16(2-3):243-261 discussion p 279-84.
144. Axelrod J. Phospholipase A2 and G proteins. Trends Neurosci 1995;18(2):64-65.
145. Chang MC, Contreras MA, Rosenberger TA, Rintala JJ, Bell JM, Rapoport SI. Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J Neurochem 2001;77(3):796-803.
146. Chang MC, Grange E, Rabin O, Bell JM, Allen DD, Rapoport SI. Lithium decreases turnover of arachidonate in several brain phospholipids. Neurosci Lett 1996;220(3):171-174.
147. Rapoport SI, Bosetti F. Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch Gen Psychiatry 2002;59(7):592-596.
148. Chang MC, Jones CR. Chronic lithium treatment decreases brain phospholipase A2 activity. Neurochem Res 1998;23(6):887-892.
149. Rintala J, Seemann R, Chandrasekaran K, Rosenberger TA, Chang L, Contreras MA, et al. 85 kDa cytosolic phospholipase A2 is a target for chronic lithium in rat brain. Neuroreport 1999;10(18):3887-3890.
150. Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci 2001;2(1):24-32.
151. Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol 2001;11(3):272-280.
152. Riccio A, Pierchala BA, Ciarallo CL, Ginty DD. An NGF-Trk-Amediated retrograde signal to transcription factor CREB in sympathetic neurons. Science 1997;277(5329):1097-1100.
153. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999;286(5443):1358-1362.
154. Suzuki T, Okumura-Noji K, Nishida E. ERK2-type mitogen-activated protein kinase (MAPK) and its substrates in postsynaptic density fractions from the rat brain. Neurosci Res 1995;22(3):277-285.
155. Matsubara M, Kusubata M, Ishiguro K, Uchida T, Titani K, Taniguchi H. Site-specific phosphorylation of synapsin I by mitogenactivated protein kinase and Cdk5 and its effects on physiological functions. J Biol Chem 1996;271(35):21108-21113.
156. Kornhauser JM, Greenberg ME. A kinase to remember: dual roles for MAP kinase in long-term memory. Neuron 1997;18(6):839-842.
157. Fukunaga K, Miyamoto E. Role of MAP kinase in neurons. Mol Neurobiol 1998;16(1):79-95.
158. Robinson MJ, Stippec SA, Goldsmith E, White MA, Cobb MH. A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol 1998;8(21):1141-1150.
159. Xu Q, Fawcett TW, Gorospe M, Guyton KZ, Liu Y, Holbrook NJ. Induction of mitogen-activated protein kinase phosphatase-1 during acute hypertension. Hypertension 1997;30(1 Pt 1):106-111.
160. Roberson ED, English JD, Adams JP, Selcher JC, Kondratick C, Sweatt JD. The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus. J Neurosci 1999;19(11):4337-4348.
161. Roberson ED, English JD, Sweatt JD. A biochemist's view of longterm potentiation. Learn Mem 1996;3(1):1-24.
162. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999;72(2):879-882.
163. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 1999;46(7):929-940.
164. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999;274(10):6039-6042.
165. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001;158(1):100-106.
166. Chen G, Einat H, Yuan P, Manji HK. Evidence for the Involvement of the ERK MAP kinase signaling cascade in mood modulation. Biol Psychiatry 2002;51(8):3685.
167. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J Biol Chem 2001;276(34):31674-31683.
168. Chuang DM, Chen R, Chalecka-Franaszek E, Ren M, Hashimoto R, Senatorov V, et al. Neuroprotective effects of lithium in cultured cells and animal model of diseases. Bipolar Disord 2002;4:129-136.
169. Jope RS, Bijur GN. Mood stabilizers, glycogen synthase kinase-3b and cell survival. Mol Psychiatry 2002;7:S35-S45.
170. Inouye M, Yamamura H, Nakano A. Lithium delays the radiation-induced apoptotic process in external granule cells of mouse cerebellum. J Radiat Res (Tokyo) 1995;36(3):203-208.
171. + protection of cerebellar granule neurons switched to non-depolarizing medium. Eur J Pharmacol. 1996;315(1):111-114.
172. Li, R., Shen Y, El-Mallakh RS. Lithium protects against ouabain-induced cell death. Lithium 1994;5(4):211-216.
173. Volonte C, Rukenstein A. Lithium chloride promotes short-term survival of PC12 cells after serum and NGF deprivation. Lithium 1993;4(3):211-219.
174. D'Mello SR, Anelli R, Calissano P. Lithium induces apoptosis in immature cerebellar granule cells but promotes survival of mature neurons. Exp Cell Res 1994;211(2):332-338.
175. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000;48(8):740-754.
176. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000;48(8):766-777.
177. Rajkowska G. Cell pathology in bipolar disorder. Bipolar Disord 2002;4:105-116.
178. Harrison PJ. The neuropathology of primary mood disorder. Brain 2002;125(Pt 7):1428-1449.
179. Miguel-Hidalgo JJ, Rajkowska G. Morphological brain changes
180. Drevets WC, Gadde K, Krishnan R. Neuroimaging studies of depression. In: Charney DS, Nester EJ, Bunney BS, editors. Neurobiology of mental illness, New York: Oxford University Press, 1999. pp. 394-418.
181. Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, et al. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 2001;106(3):603-612.
182. Nonaka S, Chuang DM. Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 1998;9(9):2081-2084.
183. Bruno V, Sortino MA, Scapagnini U, Nicoletti F, Canonico PL. Antidegenerative effects of Mg(2 + )-valproate in cultured cerebellar neurons. Funct Neurol 1995;10(3):121-130.
184. 2+ deregulation, and cytoskeletal pathology. Neurobiol Aging 1995;16(2):187-198.
185. +. Eur J Biochem 1999;266(3):886-891.
186. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. J Neurochem 2002;80(4):589-597.
187. Bijur GN, De Sarno P, Jope RS. Glycogen synthase kinase-3beta facilitates staurosporine- and heat shock-induced apoptosis. Protection by lithium. J Biol Chem 2000;275(11):7583-7590.
188. Inestrosa NC, Alvarez A, Godoy J, Reyes A, De Ferrari GV. Acetylcholinesterase-amyloid-beta-peptide interaction and Wnt signaling involvement in Abeta neurotoxicity. Acta Neurol Scand Suppl 2000;176:53-59.
189. Dong LP, Wang TY, Zhu J. Effects of carbamazepine on hypoxic and ischemic brain damage in mice [in Chinese]. Zhongguo Yao Li Xue Bao 1994;15(3):257-259.
190. Moore GJ, Bebchuk JM, Hasanat K, Chen G, Seraji-Bozorgzad N, Wilds IB, et al. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects? Biol Psychiatry 2000;48(1):1-8.
191. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithiuminduced increase in human brain grey matter. Lancet 2000;356(9237):1241-1242.
192. Soares JC. Can brain-imaging studies provide a 'mood stabilizer signature'? Mol Psychiatry 2002;71:S64-S70.
193. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Austr 1949;2:349-352.
194. Lenox RH, Hahn CG. Overview of the mechanism of action of lithium in the brain: fifty-year update. J Clin Psychiatry 2000;61(Suppl 9):5-15.
195. Shaldubina A, Agam G, Belmaker RH. The mechanism of lithium action: state of the art, ten years later. Prog Neuropsychopharmacol Biol Psychiatry 2001;25(4):855-866.
196. Nakashima K, Tuboi S. Size-dependent allosteric effects of monovalent cations on rabbit liver fructose-1,6-bisphosphatase. J Biol Chem 1976;251(14):4315-4321.
197. Nordenberg J, Kaplansky M, Beery E, Klein S, Beitner R. Effects of lithium on the activities of phosphofructokinase and phosphoglucomutase and on glucose-1,6-diphosphate levels in rat muscles, brain and liver. Biochem Pharmacol 1982;31(6):1025-1031.
198. Yenush L, Belles JM, Lopez-Coronado JM, Gil-Mascarell R, Serrano R, Rodriguez PL. A novel target of lithium therapy. FEBS Lett 2000;467(2-3):321-325.
199. Rhyu GI, Ray Jr WJ, Markley JL. Enzyme-bound intermediates in the conversion of glucose 1-phosphate to glucose 6-phosphate by phosphoglucomutase. Phosphorus NMR studies. Biochemistry 1984;23(2):252-260.
200. Ray Jr WJ, Szymanki ES, Ng L. The binding of lithium and of anionic metabolites to phosphoglucomutase. Biochim Biophys Acta 1978;522(2):434-442.
201. Martinez A, Castro A, Dorronsoro I, Alonso M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002;22(4):373-384.
202. Emrich HM, von Zerssen D, Kissling W, Moller HJ, Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr 1980;229(1):1-16.
203. Lambert PA, Venaud G. Use of valpromide in psychiatric therapeutics [in French]. Encephale 1987;13(6):367-373.
204. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. The Depakote Mania Study Group. J Am Med Assoc 1994;271(12):918-924.
205. Pope Jr HG, McElroy SL, Keck Jr PE, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991;48(1):62-68.
206. Lemperiere T. Brief history of the development of valproate in bipolar disorders [in French]. Encephale 2001;27(4):365-372.
207. Lambert PA, Venaud G. Comparative study of valpromide versus lithium in the treatment of affective disorders. Nervure 1992;5:57-65.
208. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57(5):481-489.
209. Macdonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36(Suppl 2):S2-12.
210. Johannessen CU. Mechanisms of action of valproate: a commentary. Neurochem Int 2000;37(2-3):103-110.
211. van der Laan JW, de Boer T, Bruinvels J. Di-n-propylacetate and GABA degradation. Preferential inhibition of succinic semialdehyde dehydrogenase and indirect inhibition of GABA-transaminase. J Neurochem 1979;32(6):1769-1780.
212. Anlezark GM, Horton RW, Meldrum BS, Sawaya MC, Stephenson JD. Proceedings: gamma-Aminobutyric acid metabolism and the anticonvulsant action of ethanolamine-o-sulphate and di-n-propylacetate. Br J Pharmacol 1976;56(3):383-384.
213. Sawaya MC, Horton RW, Meldrum BS. Effects of anticonvulsant drugs on the cerebral enzymes metabolizing GABA. Epilepsia 1975;16(4):649-655.
214. Whittle SR, Turner AJ. Effects of the anticonvulsant sodium valproate on gamma-aminobutyrate and aldehyde metabolism in ox brain. J Neurochem 1978;31(6):1453-1459.
215. Balazs R, Machiyama Y, Hammond BJ, Julian T, Richter D. The operation of the gamma-aminobutyrate bypath of the tricarboxylic acid cycle in brain tissue in vitro. Biochem J 1970;116(3):445-461.
216. Leiderman DB, Balish M, Bromfield EB, Theodore WH. Effect of valproate on human cerebral glucose metabolism. Epilepsia 1991;32(3):417-422.
217. 15O water positron emission tomography study. Epilepsia 1996;37(6):515-521.
218. Godin Y, Heiner L, Mark J, Mandel P. Effects of DI-n-propylacetate, and anticonvulsive compound, on GABA metabolism. J Neurochem 1969;16(3):869-873.
219. Loscher W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem Res 1993;18(4):485-502.
220. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20(24):6969-6978.
221. Loscher W, Nau H. Pharmacological evaluation of various metabolites and analogues of valproic acid. Anticonvulsant and toxic potencies in mice. Neuropharmacology 1985;24(5):427-435.
222. Radatz M, Ehlers K, Yagen B, Bialer M, Nau H. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res 1998;30(1):41-48.
223. Lampen A, Siehler S, Ellerbeck U, Gottlicher M, Nau H. New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta). Toxicol Appl Pharmacol 1999;160(3):238-249.
224. Nau H, Hauck RS, Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 1991;69(5):310-321.
225. Dehing J. Studies on the psychotropic action of Tegretol. Acta Neurol Psychiatr Belg 1968;68(12):895-905.
226. Dalby MA. Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of psychomotor epilepsy. Epilepsia 1971;12(4):325-334.
227. Takezaki H, Hanaoka M. The use of carbamazepine (tegretol) in the control of manic-depressive psychosis and other manic, depressive states. Clin Psychiatry 1971;13:173-192.
228. Okuma T, Kishimoto A, Inoue K, Matsumoto H, Ogura A. Antimanic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatr Neurol Jpn 1973;27(4):283-297.
229. Albright PS, Burnham WM. Development of a new pharmacological seizure model: effects of anticonvulsants on cortical- and amygdalakindled seizures in the rat. Epilepsia 1980;21(6):681-689.
230. Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: a preliminary report. Commun Psychopharmacol 1978;2(2):159-175.
231. McLean MJ, Macdonald RL. Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J Pharmacol Exp Ther 1983;227(3):779-789.
232. Schwarz JR, Grigat G. Phenytoin and carbamazepine: potential- and frequency-dependent block of Na currents in mammalian myelinated nerve fibers. Epilepsia 1989;30(3):286-294.
233. Courtney KR, Etter EF. Modulated anticonvulsant block of sodium channels in nerve and muscle. Eur J Pharmacol 1983;88(1):1-9.
234. Van Calker D, Biber K, Walden J, Gebicke P, Berger M. Carbamazepine and adenosine receptors. In: Manji HK, Bowden CL, Belmaker RH, editors. Bipolar medications: mechanisms of action, Washington, DC: American Psychiatric Press, 2000. pp. 331-345.
235. Skerritt JH, Johnston GA, Chow SC. Interactions of the anticonvulsant carbamazepine with adenosine receptors. 2. Pharmacological studies. Epilepsia 1983;24(5):643-650.
236. Marangos PJ, Post RM, Patel J, Zander K, Parma A, Weiss S. Specific and potent interactions of carbamazepine with brain adenosine receptors. Eur J Pharmacol 1983;93(3-4):175-182.
237. Skeritt JH, Davies LP, Johnston GA. A purinergic component in the anticonvulsant action of carbamazepine? Eur J Pharmacol 1982;82(3-4):195-197.
238. Weir RL, Padgett W, Daly JW, Anderson SM. Interaction of anticonvulsant drugs with adenosine receptors in the central nervous system. Epilepsia 1984;25(4):492-498.
239. Durcan MJ, Morgan PF. Prospective role for adenosine and adenosinergic systems in psychiatric disorders. Psychol Med 1990;20(3):475-486.
240. Marangos PJ, Weiss SR, Montgomery P, Patel J, Narang PK, Cappabianca AM, et al. Chronic carbamazepine treatment increases brain adenosine receptors. Epilepsia 1985;26(5):493-498.
241. Marangos PJ, Montgomery P, Weiss SR, Patel J, Post RM. Persistent upregulation of brain adenosine receptors in response to chronic carbamazepine treatment. Clin Neuropharmacol 1987;10(5):443-448.
242. Biber K, Walden J, Gebicke-Harter P, Berger M, van Calker D. Carbamazepine inhibits the potentiation by adenosine analogues of agonist induced inositolphosphate formation in hippocampal astrocyte cultures. Biol Psychiatry 1996;40(7):563-567.
243. Pacheco MA, Jope RS. Modulation of carbachol-stimulated AP-1 DNA binding activity by therapeutic agents for bipolar disorder in human neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res 1999;72(2):138-146.
244. Hua LV, Green M, Wong A, Warsh JJ, Li PP. Tetraspan protein CD151: a common target of mood stabilizing drugs? Neuropsychopharmacology 2001;25(5):729-736.
245. Lee Y, Hamamura T, Ohashi K, Miki M, Fujiwara Y, Kuroda S. Carbamazepine suppresses methamphetamine-induced Fos expression in a regionally specific manner in the rat brain. Possible neural substrates responsible for antimanic effects of mood stabilizers. Neuropsychopharmacology 2000;22(5):530-537.
246. Tolle TR, Castro-Lopes JM, Schadrack J, Evan G, Zieglgansberger W. Anticonvulsants suppress c-Fos protein expression in spinal cord neurons following noxious thermal stimulation. Exp Neurol 1995;132(2):271-278.
247. Gunn AJ, Dragunow M, Faull RL, Gluckman PD. Effects of hypoxia-ischemia and seizures on neuronal and glial-like c-fos protein levels in the infant rat. Brain Res 1990;531(1-2):105-116.
248. Gurvich N, Klein PS. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacology and Therapeutics 2003;96:45-66.